The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnology’s PDMonitor system for Parkinson’s disease patients.
The institute and the research/support organization will collaborate on development of novel therapies aimed at treating the central nervous system disorder.
The Parkinson’s Progression Markers Initiative, built using Evidation Health’s research platform, aims to triple enrollment and recruit online participants.
The biotech firm has presented data from a study that could offer hope to patients with Parkinson’s, Gaucher, Alzheimer’s and other neurodegenerative conditions.
In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinson’s cohort, to aid future research.
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
Large clinical trials can be particularly useful in the early treatment and prevention of neurodegenerative diseases because of the amount of data collected, though patient recruitment and retention are challenging, says biostatistician.
Centogene and Denali entered a strategic collaboration to identify and recruit patients with a gene mutation to be enrolled in a Parkinson’s disease study.
A Swedish company’s combination gel and pump delivery system, Lecigon, has received regulatory approval for the treatment of patients with advanced Parkinson’s disease.
MSD has warned regulators to expect a shortage of its Parkinson’s medicine, Sinemet, due to production constraints at a contract manufacturer’s facility.
Impax Laboratories said it is working to address issues raised in an FDA Form 483 for its Taiwanese manufacturing facility, which was cited with 10 observations following an inspection in late July.
US life science firm Sigma-Aldrich has received a Michael J Fox Foundation (MJFF) grant to create knockout-rat models of Parkinson’s disease (PD) to improve preclinical drug development.
Finnish drugmaker Orion is to follow through on plans to cut its R&D workforce and shed 205 employees to sure up operations as generic pressure mounts on its leading Parkinson’s disease drugs.
Schwarz Pharma's foray into the central nervous system
disorder market is beginning to pay serious dividends as the
firm's ground-breaking transdermal patch for Parkinson's continues
to prove a success story, now gaining...
Oxford Biomedica has made available preclinical efficacy data,
which suggests that gene-based product could have significant
efficacy for those suffering from Parkinson's disease when compared
to current treatment methods.
A simple laboratory method to treat Parkinson's disease, which
involves electric currents, has been developed by researchers, who
believe the use of this method will reduce or eliminate the need to
treat this disorder with drug...
Scientists researching pharmaceutical treatments for Parkinson's
disease are invited to submit study information to a new patient
website, which is intended to improve access to information on
Parkinson's clinical trials,...
Research that could eventually lead to gene therapy treatment
options for patients with Parkinson's disease has been published
this week, which could bring hope to more than 1 million Americans
each year who suffer from this...
German, US and Canadian researchers have discovered a gene and six
mutations that cause symptoms associated with Parkinson's disease
and other neurodegenerative disorders.
A research team based in Sweden is benefiting from a medical
charity grant of $3 million (€2.5m) that will help it develop a new
cell-based therapy for Parkinson's. Current therapies can only
ameliorate the symptoms of the disease.
